Both in vitro and in vivo experiments in mice have demonstrated that VY-3-135 could inhibit tumor growth, and VY-3-135 tested in human breast models yielded similar results, namely, tumors with a high ACSS2 expression were more sensitive to treatment and significantly inhibited tumor growth [104]. This evidence concerns the gene ACSS2 and neoplasm.